Kanabo Group PLC
LSE:KNB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Kanabo Group PLC
Net Income (Common)
Kanabo Group PLC
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kanabo Group PLC
LSE:KNB
|
Net Income (Common)
-£8m
|
CAGR 3-Years
-294%
|
CAGR 5-Years
-119%
|
CAGR 10-Years
N/A
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Net Income (Common)
£5.7B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-4%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Net Income (Common)
$10.2B
|
CAGR 3-Years
46%
|
CAGR 5-Years
26%
|
CAGR 10-Years
14%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Net Income (Common)
$485m
|
CAGR 3-Years
37%
|
CAGR 5-Years
2%
|
CAGR 10-Years
7%
|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Net Income (Common)
-£49m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-23%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Net Income (Common)
-£10.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Kanabo Group PLC
Glance View
Kanabo Group Plc engages in the acquisition of a target company and business in the energy and industrial sectors. The firm is principally focused on distribution of cannabis-derived products for medical patients, and non- tetrahydrocannabinol (THC) products for Cannabidiol (CBD) consumers. The company has developed a formula for sleep disorders (insomnia), three CBD formulations for Reload, Relax, and Repair, and the VapePod, which is a vaporization delivery system for cannabis extract. The firm's R&D lab is set up in the Weizmann Science Park. The firm's clinical and validation activities, including safety and efficiency tests, are conducted in Israel. The firm is selling its initial products in Europe. The company is also engaged in conducting research and development (R&D) to develop cannabis oil formulas, medical-grade vaporizers, and various non-smoking consumption solutions.
See Also
What is Kanabo Group PLC's Net Income (Common)?
Net Income (Common)
-8m
GBP
Based on the financial report for Dec 31, 2023, Kanabo Group PLC's Net Income (Common) amounts to -8m GBP.
What is Kanabo Group PLC's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-119%
Over the last year, the Net Income (Common) growth was -16%. The average annual Net Income (Common) growth rates for Kanabo Group PLC have been -294% over the past three years , -119% over the past five years .
